262 related articles for article (PubMed ID: 11454884)
21. Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: The European Organization for Research and Treatment of Cancer 10961 Multicenter Phase III Trial.
Biganzoli L; Cufer T; Bruning P; Coleman R; Duchateau L; Calvert AH; Gamucci T; Twelves C; Fargeot P; Epelbaum R; Lohrisch C; Piccart MJ
J Clin Oncol; 2002 Jul; 20(14):3114-21. PubMed ID: 12118025
[TBL] [Abstract][Full Text] [Related]
22. Docetaxel in combination chemotherapy for metastatic breast cancer.
Khayat D; Antoine E
Semin Oncol; 1997 Aug; 24(4 Suppl 13):S13-19-S13-26. PubMed ID: 9335513
[TBL] [Abstract][Full Text] [Related]
23. Salvage treatment of metastatic breast cancer with docetaxel and carboplatin. A multicenter phase II trial.
Mavroudis D; Alexopoulos A; Malamos N; Ardavanis A; Kandylis C; Stavrinidis E; Kouroussis Ch; Agelaki S; Androulakis N; Bozionelou V; Georgoulias V
Oncology; 2003; 64(3):207-12. PubMed ID: 12697959
[TBL] [Abstract][Full Text] [Related]
24. Phase II study of oral vinorelbine in combination with capecitabine as second line chemotherapy in metastatic breast cancer patients previously treated with anthracyclines and taxanes.
Jones A; O'Brien M; Sommer H; Nowara E; Welt A; Pienkowski T; Rolski J; Pham ML; Perraud K; Trillet-Lenoir V
Cancer Chemother Pharmacol; 2010 Mar; 65(4):755-63. PubMed ID: 19669644
[TBL] [Abstract][Full Text] [Related]
25. Long-survival in responding patients with metastatic breast cancer treated with doxorubicin-docetaxel combination. A multicentre phase II trial.
Mattioli R; Lippe P; Massacesi C; Cappelletti C; Nacciarriti D; Bisonni R; Graziano F; Menichetti ET; Imperatori L; Testa E; Laici G; Balletra A; Silva RR
Anticancer Res; 2004; 24(5B):3257-61. PubMed ID: 15510620
[TBL] [Abstract][Full Text] [Related]
26. Epirubicin--docetaxel combination in first-line chemotherapy for patients with metastatic breast cancer: final results of a dose-finding and efficacy study.
Viens P; Roché H; Kerbrat P; Fumoleau P; Guastalla JP; Delozier T
Am J Clin Oncol; 2001 Aug; 24(4):328-35. PubMed ID: 11474255
[TBL] [Abstract][Full Text] [Related]
27. A clinical phase II study of a non-anthracycline sequential combination of cisplatin-vinorelbine followed by docetaxel as first-line treatment in metastatic breast cancer.
Shamseddine AI; Otrock ZK; Khalifeh MJ; Yassine HR; Charafeddine M; Abdel-Khalek Z; Chehal A; Bitar N; Jalloul R; Dheiny M; Dandashi A; Wehbeh M; El-Saghir NS
Oncology; 2006; 70(5):330-8. PubMed ID: 17164589
[TBL] [Abstract][Full Text] [Related]
28. Combination versus sequential doxorubicin and docetaxel as primary chemotherapy for breast cancer: A randomized pilot trial of the Hoosier Oncology Group.
Miller KD; McCaskill-Stevens W; Sisk J; Loesch DM; Monaco F; Seshadri R; Sledge GW
J Clin Oncol; 1999 Oct; 17(10):3033-7. PubMed ID: 10506597
[TBL] [Abstract][Full Text] [Related]
29. Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer.
Chan S; Friedrichs K; Noel D; Pintér T; Van Belle S; Vorobiof D; Duarte R; Gil Gil M; Bodrogi I; Murray E; Yelle L; von Minckwitz G; Korec S; Simmonds P; Buzzi F; González Mancha R; Richardson G; Walpole E; Ronzoni M; Murawsky M; Alakl M; Riva A; Crown J;
J Clin Oncol; 1999 Aug; 17(8):2341-54. PubMed ID: 10561296
[TBL] [Abstract][Full Text] [Related]
30. Treatment of advanced breast cancer with vinorelbine and docetaxel with or without human granulocyte colony-stimulating factor.
Kornek GV; Ulrich-Pur H; Penz M; Haider K; Kwasny W; Depisch D; Kovats E; Lang F; Schneeweiss B; Scheithauer W
J Clin Oncol; 2001 Feb; 19(3):621-7. PubMed ID: 11157011
[TBL] [Abstract][Full Text] [Related]
31. Docetaxel administered on a weekly basis for metastatic breast cancer.
Burstein HJ; Manola J; Younger J; Parker LM; Bunnell CA; Scheib R; Matulonis UA; Garber JE; Clarke KD; Shulman LN; Winer EP
J Clin Oncol; 2000 Mar; 18(6):1212-9. PubMed ID: 10715290
[TBL] [Abstract][Full Text] [Related]
32. Toxicity of dose-dense docetaxel followed by doxorubicin with cyclophosphamide as adjuvant therapy for breast cancer in a phase II study.
Lambert-Falls R; Modugno S
Clin Breast Cancer; 2007 Aug; 7(9):697-704. PubMed ID: 17919350
[TBL] [Abstract][Full Text] [Related]
33. Docetaxel (Taxotere) plus doxorubicin-based combinations: the evidence of activity in breast cancer.
Nabholtz JM
Semin Oncol; 1999 Jun; 26(3 Suppl 9):7-13. PubMed ID: 10426453
[TBL] [Abstract][Full Text] [Related]
34. A randomized phase II study of alternating and sequential regimens of docetaxel and doxorubicin as first-line chemotherapy for metastatic breast cancer.
Paridaens R; Van Aelst F; Georgoulias V; Samonnig H; Cocquyt V; Zielinski C; Hausmaninger H; Willemse P; Boudraa Y; Wildiers J; Ramazeilles C; Azli N
Ann Oncol; 2003 Mar; 14(3):433-40. PubMed ID: 12598350
[TBL] [Abstract][Full Text] [Related]
35. Phase I trial of pegylated liposomal doxorubicin and docetaxel in advanced breast cancer.
Sparano JA; Malik U; Rajdev L; Sarta C; Hopkins U; Wolff AC
J Clin Oncol; 2001 Jun; 19(12):3117-25. PubMed ID: 11408509
[TBL] [Abstract][Full Text] [Related]
36. Vinorelbine and docetaxel as first-line chemotherapy in metastatic breast cancer.
Vassilomanolakis M; Koumakis G; Drufakou S; Aperis G; Demiri M; Barbounis V; Missitzis J; Efremidis AP
Cancer Chemother Pharmacol; 2003 Feb; 51(2):179-83. PubMed ID: 12647021
[TBL] [Abstract][Full Text] [Related]
37. Phase II study of pegylated liposomal doxorubicin (Caelyx) and docetaxel as first-line treatment in metastatic breast cancer.
Alexopoulos A; Karamouzis MV; Stavrinides H; Ardavanis A; Kandilis K; Stavrakakis J; Georganta C; Rigatos G
Ann Oncol; 2004 Jun; 15(6):891-5. PubMed ID: 15151945
[TBL] [Abstract][Full Text] [Related]
38. Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study.
Gianni L; Munzone E; Capri G; Fulfaro F; Tarenzi E; Villani F; Spreafico C; Laffranchi A; Caraceni A; Martini C
J Clin Oncol; 1995 Nov; 13(11):2688-99. PubMed ID: 7595726
[TBL] [Abstract][Full Text] [Related]
39. Phase III study of doxorubicin/cyclophosphamide with concomitant versus sequential docetaxel as adjuvant treatment in patients with human epidermal growth factor receptor 2-normal, node-positive breast cancer: BCIRG-005 trial.
Eiermann W; Pienkowski T; Crown J; Sadeghi S; Martin M; Chan A; Saleh M; Sehdev S; Provencher L; Semiglazov V; Press M; Sauter G; Lindsay MA; Riva A; Buyse M; Drevot P; Taupin H; Mackey JR
J Clin Oncol; 2011 Oct; 29(29):3877-84. PubMed ID: 21911726
[TBL] [Abstract][Full Text] [Related]
40. Phase II clinical and pharmacological study of pirarubicin in combination with 5-fluorouracil and cyclophosphamide in metastatic breast cancer.
Dhingra K; Frye D; Newman RA; Walters R; Theriault R; Fraschini G; Smith T; Buzdar A; Hortobagyi GN
Clin Cancer Res; 1995 Jul; 1(7):691-7. PubMed ID: 9816034
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
